Aspire Biopharma Holdings, Inc.
ASBP
$0.3366
-$0.0277-7.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.37M | 2.01M | 1.07M | 608.30K | 423.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.11M | 2.41M | 1.21M | 646.80K | 469.70K |
| Operating Income | -3.11M | -2.41M | -1.21M | -646.80K | -469.70K |
| Income Before Tax | -18.90M | -17.02M | -1.31M | -646.80K | -469.70K |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.50K | 500.00 |
| Earnings from Continuing Operations | -18.90 | -17.02 | -1.31 | -0.65 | -0.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.90M | -17.02M | -1.31M | -648.30K | -470.20K |
| EBIT | -3.11M | -2.41M | -1.21M | -646.80K | -469.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.46 | -0.43 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.05 | -0.03 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.46 | -0.43 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.05 | -0.03 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 970.55M | 948.81M | 938.52M | 941.52M | 498.20M |
| Average Diluted Shares Outstanding | 970.55M | 948.81M | 938.52M | 941.52M | 498.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |